GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice.
In mice, diabetes can be induced by multiple low doses of streptozotocin (MLD-STZ), i.e., 40 mg/kg body wt on each of 5 consecutive days. In this model, diabetes develops only when STZ induces both beta-cell toxicity and T-cell-dependent immune reactions. The target molecule(s) of MLD-STZ-induced beta-cell toxicity are not known, however. In this study, we report that GLUT2 is a target molecule for MLD-STZ toxicity. Ex vivo, a gradual decrement of both GLUT2 protein and mRNA expression was found in pancreatic islets isolated from MLD-STZ-treated C57BL/6 male mice, whereas mRNA expression of beta-actin, glucokinase, and proinsulin remained unaffected. Significant reduction of both GLUT2 protein and mRNA expression was first noted 1 day after the third STZ injection, clearly preceding the onset of hyperglycemia. The extent of reduction increased with the number of STZ injections administered and increased over time, after the last, i.e., fifth, STZ injection. The STZ-induced reduction of GLUT2 protein and mRNA was not due to an essential loss of beta-cells, because ex vivo, not only the total RNA yield and protein content in isolated islets, but also proinsulin mRNA expression, failed to differ significantly in the differently treated groups. Furthermore, islets isolated from MLD-STZ-treated donors responded to the nonglucose secretagogue arginine in a pattern similar to that of solvent-treated donors. Interestingly, the MLD-STZ-induced reduction of both GLUT2 protein and mRNA was prevented by preinjecting mice with 5-thio-D-glucose before each STZ injection. Apparently, GLUT2 is a crucial target molecule of MLD-STZ toxicity, and this toxicity seems to precede the immune reactions against beta-cells.
Wang
Z
Z
Clinical Experimental Department, Diabetes Research Institute, Heinrich-Heine University of Düsseldorf, Germany.
Gleichmann
H
H
D000199:Actins / Q000032:analysis / Q000235:genetics / Q000378:metabolism; D000818:Animals; D001483:Base Sequence; D001786:Blood Glucose / Q000032:analysis / Q000378:metabolism; D015153:Blotting, Western; D002478:Cells, Cultured; D018076:DNA, Complementary / Q000032:analysis / Q000737:chemistry / Q000235:genetics; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005786:Gene Expression Regulation; D005941:Glucokinase / Q000032:analysis / Q000235:genetics / Q000378:metabolism; D005947:Glucose / Q000031:analogs & derivatives / Q000494:pharmacology; D051273:Glucose Transporter Type 2; D007515:Islets of Langerhans / Q000737:chemistry* / Q000196:embryology / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008954:Models, Biological; D009004:Monosaccharide Transport Proteins / Q000032:analysis* / Q000235:genetics / Q000378:metabolism; D016133:Polymerase Chain Reaction; D011384:Proinsulin / Q000032:analysis / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000032:analysis / Q000737:chemistry / Q000235:genetics; D011863:Radioimmunoassay; D013311:Streptozocin / Q000008:administration & dosage*
D000199:Actins; D001786:Blood Glucose; D018076:DNA, Complementary; D051273:Glucose Transporter Type 2; D009004:Monosaccharide Transport Proteins; D012333:RNA, Messenger; C003002:5-thio-D-glucose; D013311:Streptozocin; D011384:Proinsulin; D005941:Glucokinase; D005947:Glucose